Abstract: We report a 37-year-old male with metastatic lung adenocarcinoma who developed Stevens-Johnson syndrome (SJS) after 13 doses of tislelizumab and one-month administration of furmonertinib. The rash erupted after one day of treatment of anlotinib. Immune checkpoint inhibitors, epidermal growth factor inhibitors, and multi-kinase inhibitors can cause keratinocytes apoptosis, leading to SJS/TEN. SJS/TEN caused by immunotherapy is characterized by severe conditions and high mortality. The consequential use of target therapy following immunotherapy increase the incidence of serious cutaneous adverse events. In this case, tislelizumab is the cornerstone of SJS/TEN, furmonertinib is an inducement, whereas anlotinib aggravated the rash. Anti-allergic before the introduction of target therapy following with immunotherapy may be necessary.

Key words: tislelizumab, furmonertinib, anlotinib, Stevens-Johnson syndrome, toxic epidermal necrolysis